Abstract
The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Current Pharmaceutical Design
Title:Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Volume: 18 Issue: 12
Author(s): Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl
Affiliation:
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Abstract: The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Export Options
About this article
Cite this article as:
Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl , Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958594
DOI https://dx.doi.org/10.2174/138161212799958594 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Translational Challenge Models in Support of Efficacy Studies: Neurobehavioral and Cognitive Changes Induced by Transcranial Magnetic Stimulation in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Ecto-Nucleotidase Inhibitors: Recent Developments in Drug Discovery
Mini-Reviews in Medicinal Chemistry Mind-Body Practices and the Adolescent Brain: Clinical Neuroimaging Studies
Adolescent Psychiatry NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Brain Derived Neurotrophic Factor and Cognitive Status: The Delicate Balance Among People Living with HIV, with and without Alcohol Abuse
Current HIV Research Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry The Impact of Marijuana Use on Memory in HIV-Infected Patients: A Comprehensive Review of the HIV and Marijuana Literatures
Current Drug Abuse Reviews Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review
Current Topics in Medicinal Chemistry Pharmacology of Ultrasonic Vocalizations in adult Rats: Significance, Call Classification and Neural Substrate
Current Neuropharmacology